CN105939730B - MERS-CoV疫苗 - Google Patents

MERS-CoV疫苗 Download PDF

Info

Publication number
CN105939730B
CN105939730B CN201480074433.XA CN201480074433A CN105939730B CN 105939730 B CN105939730 B CN 105939730B CN 201480074433 A CN201480074433 A CN 201480074433A CN 105939730 B CN105939730 B CN 105939730B
Authority
CN
China
Prior art keywords
mers
cov
seq
spike
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480074433.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105939730A (zh
Inventor
大卫·B·韦纳
卡鲁皮亚·穆苏马尼
尼兰詹·Y·萨尔德赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania Penn
Priority to CN202010825164.3A priority Critical patent/CN112057613A/zh
Publication of CN105939730A publication Critical patent/CN105939730A/zh
Application granted granted Critical
Publication of CN105939730B publication Critical patent/CN105939730B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480074433.XA 2013-11-29 2014-11-26 MERS-CoV疫苗 Active CN105939730B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010825164.3A CN112057613A (zh) 2013-11-29 2014-11-26 MERS-CoV疫苗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29
US61/910,153 2013-11-29
PCT/US2014/067537 WO2015081155A1 (en) 2013-11-29 2014-11-26 Mers-cov vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010825164.3A Division CN112057613A (zh) 2013-11-29 2014-11-26 MERS-CoV疫苗

Publications (2)

Publication Number Publication Date
CN105939730A CN105939730A (zh) 2016-09-14
CN105939730B true CN105939730B (zh) 2020-09-11

Family

ID=53199622

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480074433.XA Active CN105939730B (zh) 2013-11-29 2014-11-26 MERS-CoV疫苗
CN202010825164.3A Pending CN112057613A (zh) 2013-11-29 2014-11-26 MERS-CoV疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010825164.3A Pending CN112057613A (zh) 2013-11-29 2014-11-26 MERS-CoV疫苗

Country Status (10)

Country Link
US (5) US10016497B2 (https=)
EP (1) EP3074051A4 (https=)
JP (1) JP6412131B2 (https=)
KR (2) KR20230122181A (https=)
CN (2) CN105939730B (https=)
AU (1) AU2014354797C1 (https=)
CA (1) CA2932055A1 (https=)
IL (3) IL276210B2 (https=)
SA (1) SA516371223B1 (https=)
WO (1) WO2015081155A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112057613A (zh) * 2013-11-29 2020-12-11 宾夕法尼亚大学理事会 MERS-CoV疫苗

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134439A1 (en) 2013-03-01 2014-09-04 New York Blood Center, Inc. Immunogenic composition for mers coronavirus infection
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
WO2017044507A2 (en) * 2015-09-08 2017-03-16 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
KR102017217B1 (ko) * 2017-10-19 2019-09-02 주식회사 엔케이맥스 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
JP2023511780A (ja) * 2020-02-25 2023-03-22 イノビオ ファーマシューティカルズ，インコーポレイティド コロナウイルスに対するワクチンおよび使用方法
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
WO2021225344A1 (ko) * 2020-05-08 2021-11-11 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도
US20230226170A1 (en) * 2020-05-12 2023-07-20 Greffex, Inc. Engineering coronavirus spike proteins as vaccine antigens, their design and uses
US20230210981A1 (en) * 2020-06-09 2023-07-06 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
EP4178545A4 (en) * 2020-07-10 2024-08-07 Engimata, Inc IMMUNOGENIC COMPOSITION FORMING A VACCINE AND METHOD OF MANUFACTURE THEREOF
US20230270844A1 (en) * 2020-07-22 2023-08-31 Greffex, Inc. Multivalent beta-coronavirus vaccines, their designs and uses
JPWO2022025029A1 (https=) * 2020-07-27 2022-02-03
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
US20240016919A1 (en) * 2020-08-25 2024-01-18 The Wistar Institute Of Anatomy And Biology INTRADERMAL MERS-CoV VACCINE
US20230349889A1 (en) * 2020-09-10 2023-11-02 The Council Of The Queensland Institute Of Medical Research Methods of Determining Immune Response
AU2021340715A1 (en) * 2020-09-11 2023-04-27 Mark J. Cantwell Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
CA2819552A1 (en) * 2010-12-09 2012-06-14 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
JP2002520101A (ja) 1998-07-13 2002-07-09 ジェネトロニクス、インコーポレーテッド 電気的に補助される化粧用薬剤の局部送達法および装置
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6520950B1 (en) 1999-05-10 2003-02-18 Genetronics, Inc. Method of electroporation-enhanced delivery of active agents
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
DK1526175T4 (da) * 2003-08-18 2021-04-26 Amsterdam Inst Of Viral Genomics B V Coronavirus, nukleinsyre, protein og fremgangsmåder til generering af vaccine, lægemidler og diagnostik
AU2005250477A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
NO2324113T3 (https=) * 2008-08-08 2018-07-28
BR112014013745B1 (pt) 2011-12-09 2022-06-14 Institut Pasteur Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex
US9555094B2 (en) * 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
BR112016006122B1 (pt) 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
WO2015081155A1 (en) * 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Mers-cov vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
CA2819552A1 (en) * 2010-12-09 2012-06-14 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies;Fei Song;《J Virol.》;20130828;第87卷(第21期);11950–11954 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112057613A (zh) * 2013-11-29 2020-12-11 宾夕法尼亚大学理事会 MERS-CoV疫苗

Also Published As

Publication number Publication date
AU2014354797B2 (en) 2017-10-26
EP3074051A4 (en) 2017-04-12
US11135284B2 (en) 2021-10-05
US10548971B2 (en) 2020-02-04
AU2014354797C1 (en) 2018-02-01
KR20230122181A (ko) 2023-08-22
IL245903A0 (en) 2016-07-31
SA516371223B1 (ar) 2023-01-31
KR20160091350A (ko) 2016-08-02
IL276210A (en) 2020-09-30
IL276210B1 (en) 2023-09-01
US10016497B2 (en) 2018-07-10
WO2015081155A1 (en) 2015-06-04
CN105939730A (zh) 2016-09-14
AU2014354797A1 (en) 2016-07-07
IL305392A (en) 2023-10-01
US20210401972A1 (en) 2021-12-30
EP3074051A1 (en) 2016-10-05
IL276210B2 (en) 2024-01-01
US20190022213A1 (en) 2019-01-24
US20170258893A1 (en) 2017-09-14
IL245903B (en) 2020-08-31
JP6412131B2 (ja) 2018-10-24
US20240123056A1 (en) 2024-04-18
US11801298B2 (en) 2023-10-31
US20200222527A1 (en) 2020-07-16
CA2932055A1 (en) 2015-06-04
CN112057613A (zh) 2020-12-11
JP2016539946A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
US20240123056A1 (en) MERS-CoV Vaccine
CN102753200B (zh) 流感病毒核酸分子及由其制备的疫苗
JP6445523B2 (ja) 生体分子アジュバントを含むワクチン
JP2017535523A (ja) 抗原およびアジュバントとしてのインターロイキン−２１を有するワクチン
CN111012905B (zh) 具有作为佐剂的白介素-33的疫苗
CN103354750A (zh) 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法
HK40042641A (en) Mers-cov vaccine
US11596678B2 (en) Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR20220149907A (ko) 환자의 예방접종 및 치료를 위한 포와산(powassan) 바이러스 항원 및 관련 조성물, 및 그의 용도
HK1228285B (zh) Mers-cov疫苗
HK1228285A1 (en) Mers-cov vaccine
US20240016919A1 (en) INTRADERMAL MERS-CoV VACCINE
TW202400635A (zh) 針對sars-cov-2變異體之免疫原性組合物及其使用方法
HK40028403A (en) Vaccines with interleukin-33 as an adjuvant
HK1249066A1 (zh) Isg15和其作为佐剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228285

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant